Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Background: Thiazolidinedione (TZD) exerts anti-proliferative effects on multiple myeloma (MM) cells. However, there has not been any human study investigating the risk of MM associated with TZD use. Methods: We used Taiwan’s National Health Insurance database to identify 423,949 patients who had be...
Main Author: | Chin-Hsiao Tseng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/17/4276 |
Similar Items
-
Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A systematic review and meta-analysis
by: Cheng Yuan Xue, et al.
Published: (2022-11-01) -
Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis
by: Zhiwei Zhang, et al.
Published: (2017-04-01) -
Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients
by: Chin-Hsiao Tseng, et al.
Published: (2023-07-01) -
Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia
by: Giorgio Aquila, et al.
Published: (2022-07-01) -
The Effect of Diabetes Mellitus, Insulin, and Thiazolidinediones on Bone Histomorphometry in Streptozotocin-induced Diabetic Postmenopausal Wistar Rats
by: Derya Köseoğlu, et al.
Published: (2021-03-01)